Overview

• Amvuttra generated $492 million in second-quarter 2025 sales, topping the roughly $350 million consensus, with about 1,400 patients on therapy by quarter end.
• Alnylam raised 2025 guidance to $2.18–$2.28 billion for Amvuttra and Onpattro and projected total net revenues of $2.65–$2.8 billion.
• Priced at $476,000 annually for cardiomyopathy, Amvuttra is being approved by commercial and Medicare plans as a first-line option without required prior use of competitor therapies.
• Clinical updates included 12‑month HELIOS‑B data supporting sustained benefit and new HFSA results showing a 42% lower rate of gastrointestinal events versus placebo, including 37% with monotherapy and 49% with baseline tafamidis, with symptom reductions seen by three months.
• Alnylam’s market value has climbed above $50 billion with shares up more than 15% recently, as the company advances RNAi programs such as zilebesiran for hypertension and joins the Alliance for Genomic Discovery.